Multi-tissue microarrays (TMAs) consist of paraffin blocks in which up to 1000 separate tissue cores are assembled in array fashion to allow multiplex histological analysis. TMA can significantly accelerate the processing of a very large number of tissue specimens with excellent quality, good reliability and preservation of original tissue, with ultimate clinical benefit. We offer implementation of various commercially available TMAs to address specific aims:
Normal tissues array
Cancer samples vs. normal counterpart
Cancer vs. benign tumors
Cancer primaries vs. metastases
Cancer vs. benign lesions
Cancer samples of different morphological subtypes
Cancer samples of different clinical stages/grades
Normal tissue evaluation:
Performing human tissue evaluation for safety profile of monoclonal antibodies.
Evaluation of human versus animal tissue in rodents or primates, for selection of optimal species profile when planning your toxicology studies.
Cancer tissue evaluation:
IHC evaluation of cancer tissues for clinical trial planning, tumor/patient stratification, target cohort and market evaluation. Development of drugs targeted to interrupt specific pathways present the opportunity to conduct clinical trials that use these molecular features to select patients, assign treatment or assess treatment outcomes. Preliminary tissue profiling potentially allows the design of clinical trials with larger effect sizes and smaller sample sizes that can be completed faster.
Tissue Array Reporting Example:
Tissue MicroArray (TMA)
Smart-Assays offers a wide verity of profiling options to meet the need for antibody profiling and characterization. We establish the IHC protocol, perform the analysis and evaluate and score the results.